A Phase 4 interventional study of Metformin XR in Type 2 Diabetes Mellitus, sponsored by Bristol-Myers Squibb. Completed at 14 sites in China. Open to participants aged 17 Years to 79 Years. Per ClinicalTrials.gov, last updated 2013-08-23.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 61st largest by enrollment of the 287 interventional ones that give a count, is one of 14 that started in 2009, is one of 98 in phase 4, and was the 76th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 17 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 14 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 371 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Diabetes Mellitus, Type 2 by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 19 finished, 3 (16%) have results posted.
Among the 19 studies in Diabetes Mellitus, Type 2 by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2009, is one of 3 in phase 4, and was the 11th registered.
Bristol-Myers Squibb’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among Bristol-Myers Squibb’s 19 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Normal Weight by Body Weight Index
Drug: Metformin XR
Overweight by Body Weight Index
Drug: Metformin XR
Obese by Body Weight Index
Drug: Metformin XR
Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS)
Baseline for HbA1c is defined as that value obtained at screening visit. HbA1c was measured as a percent (%) of hemoglobin; normal range was 4.7 to 6.4% and values were obtained through a central laboratory. The Last Observation Carried Forward (LOCF) data set includes data recorded at a given visit or, if no observation is recorded at that visit, data carried forward from the previous visit.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) of Fasting Plasma Glucose (FPG) - Full Analysis Set
Baseline was defined as the value obtained at the screening visit. FPG was measured in millimoles/Liter (mmol/L) and obtained through local laboratories.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set
For fasting total cholesterol (TC), baseline is defined as Day 1 (first day of treatment). Total cholesterol was measured in millimoles per liter (mmol/L) and obtained through local laboratories.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Low-density Lipoprotein Cholesterol (LDL-C) - Full Analysis Set
Baseline was defined as values obtained on Day 1. Low-density lipoprotein cholesterol (LDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting High-density Lipoprotein Cholesterol (HDL-C) - Full Analysis Set
Baseline was defined as value obtained on Day 1 (first day of treatment). High-density lipoprotein cholesterol (HDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Triglycerides (TG) - Full Analysis Set
Baseline was defined as value obtained on Day 1 (first day of treatment). Triglycerides (TG) were measured in millimoles per liter (mmol/L)and values obtained through local laboratories.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in C-Reactive Protein (CRP) - Full Analysis Set
Baseline was defined as value obtained on Day 1 (first day of treatment). C-Reactive Protein (CRP) was measured in milligrams/liter (mg/L) and values were obtained through a central laboratory; normal was less than 5.0 mg/L.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Plasminogen Activator Inhibitor-1 (PAI-1) - Full Analysis Set
Baseline was defined as value obtained on Day 1 (first day of treatment). PAI-1 (activity) was measured in units/milliliter (U/mL)and values obtained through a central laboratory; normal was less than 25.00 U/mL.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set
Baseline was defined as value obtained on Day 1 (first day of treatment). Adiponectin was measured in milligrams/liter (mg/L) and values obtained through a central laboratory; normal range was 1.20 to 20.00 mg/L.
Time frame: Baseline to Week 16
Number of Participants With Episodes of Lactic Acidosis or Hypoglycemia From Day 1 to Week 16 - Safety Population
Day 1 was first day of treatment. Lactic acidosis defined as elevated blood lactate levels (\>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and increased lactate/pyruvate ratio. Hypoglycemia (low levels of blood glucose) was reported as an adverse event. Safety population included participants who had enrolled in the study and took at least 1 dose of glucophage extended release (glucophage XR). If a subject experienced more than one adverse event, the subject was counted once at the highest severity.
Time frame: Day 1 to Week 16
Number of Participants With Clinically Significant Changes From Baseline at Week 16 in the Hematology Laboratory Test Profile - Safety Population
Hematology profile = hematocrit, hemoglobin, red blood cell count (RBC), white blood cell count(WBC), lymphocytes, monocytes, basophils, eosinophils, neutrophils, platelet count. Baseline: value obtained at screening or last value obtained before treatment. LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): \>3 g/dL decrease from preRX; hematocrit (%): \<0.75\*preRX; RBC (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/uL): \<0.67\*LLN or \>1.5\*ULN, of if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; WBC (\*10\^3 c/uL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN, or if preRX\>ULN, use \>1.2\*preRX or \<LLN; neutrophils+bands (\*10\^3 c/uL): if value \<1.0\*10\^3 c/uL; eosinophils (\*10\^3 c/uL): if value \>0.750\*10\^3 c/uL; basophils (\*10\^3 c/uL): if value \>400/mm\^3; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL.
Time frame: Baseline to Week 16
Number of Participants Who Had Abnormal Increase From Baseline at Week 16 in Kidney or Liver Function Serum Chemistry Values - Safety Population
Baseline defined as value obtained either in screening visit or last value obtained before glucophage XR treatment given on Day 1. Serum chemistries evaluating kidney or liver function: blood urea nitrogen(BUN), serum creatinine (SCr), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total bilirubin (BR), uric acid (UA). Abnormal increase in kidney and liver function tests defined as 1.25 - less than, equal to (\<=)2.6 times (x) upper limit of normal (ULN)in ALT, AST, total BR, UA; abnormal increase defined as 1.25 to \<= 5.1 x ULN in BUN. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
Time frame: Baseline to Week 16
Number of Participants With Clinically Significant Changes From Baseline at Week 16 in Urinalysis - Safety Population
Urinalysis included pH and specific gravity. Baseline defined as values obtained at screening visit. Clinically significant: outside the reference range (low/high)and judged to be significant by the investigator: Specific gravity 1.003 - 1.035; ph 5 - 8. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week at Week 16 in ECG Parameter Heart Rate (HR) - Safety Population
Baseline was defined as ECG obtained at the screening visit. ECG was 12-lead. Heart rate (HR) was measured in beats per minute (beats/min). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
Time frame: Baseline to Week 16
Mean Change From Baseline at Week 16 in Diastolic and Systolic Blood Pressure - Safety Population
Baseline was defined as the value obtained at screening or value obtained on Day 1 before treatment. Diastolic and systolic blood pressure was measured in millimeters of mercury (mm Hg). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
Time frame: Baseline to Week 16
Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population
Baseline was defined as ECG obtained at the screening visit. A judgment of clinical significance was at the discretion of the investigator. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
Time frame: Baseline to Week 16
Started November 2009, Completed March 2011 at Peking University People's Hospital. Participants diagnosed with Type 2 diabetes mellitus 6 months prior to enrollment; were oral antidiabetic agent naive (either having received no antidiabetic agents or received agents 14 days or less, or received none within a month of enrollment in the study.
| Milestone | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Started | 125 | 122 | 124 |
| Completed | 109 | 107 | 109 |
| Not completed | 16 | 15 | 15 |
| Withdrew: Adverse event | 5 | 4 | 7 |
| Withdrew: Withdrawal by subject | 4 | 5 | 5 |
| Withdrew: Lost to follow-up | 3 | 3 | 2 |
| Withdrew: Protocol violation | 0 | 3 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 |
| Withdrew: Immigration | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 |
Baseline for HbA1c is defined as that value obtained at screening visit. HbA1c was measured as a percent (%) of hemoglobin; normal range was 4.7 to 6.4% and values were obtained through a central laboratory. The Last Observation Carried Forward (LOCF) data set includes data recorded at a given visit or, if no observation is recorded at that visit, data carried forward from the previous visit.
| percentage of hemoglobin | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS) | -1.95 ± 0.922 | -1.79 ± 0.941 | -1.68 ± 0.854 |
Baseline was defined as the value obtained at the screening visit. FPG was measured in millimoles/Liter (mmol/L) and obtained through local laboratories.
| mmol/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) of Fasting Plasma Glucose (FPG) - Full Analysis Set | -1.979 ± 1.7877 | -2.171 ± 2.1222 | -2.141 ± 2.0287 |
For fasting total cholesterol (TC), baseline is defined as Day 1 (first day of treatment). Total cholesterol was measured in millimoles per liter (mmol/L) and obtained through local laboratories.
| mmol/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set | -0.388 ± 0.9164 | -0.048 ± 0.9560 | -0.144 ± 0.8188 |
Baseline was defined as values obtained on Day 1. Low-density lipoprotein cholesterol (LDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.
| mmol/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Low-density Lipoprotein Cholesterol (LDL-C) - Full Analysis Set | -0.306 ± 0.5746 | -0.143 ± 0.6605 | -0.181 ± 0.6258 |
Baseline was defined as value obtained on Day 1 (first day of treatment). High-density lipoprotein cholesterol (HDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.
| mmol/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting High-density Lipoprotein Cholesterol (HDL-C) - Full Analysis Set | 0.056 ± 0.2016 | 0.024 ± 0.3428 | 0.032 ± 0.2042 |
Baseline was defined as value obtained on Day 1 (first day of treatment). Triglycerides (TG) were measured in millimoles per liter (mmol/L)and values obtained through local laboratories.
| mmol/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Triglycerides (TG) - Full Analysis Set | -0.172 ± 2.0678 | 0.262 ± 3.3195 | -0.041 ± 2.2018 |
Baseline was defined as value obtained on Day 1 (first day of treatment). C-Reactive Protein (CRP) was measured in milligrams/liter (mg/L) and values were obtained through a central laboratory; normal was less than 5.0 mg/L.
| mg/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in C-Reactive Protein (CRP) - Full Analysis Set | -0.589 ± 1.0914 | 3.144 ± 16.4019 | 1.633 ± 8.0706 |
Baseline was defined as value obtained on Day 1 (first day of treatment). PAI-1 (activity) was measured in units/milliliter (U/mL)and values obtained through a central laboratory; normal was less than 25.00 U/mL.
| U/mL | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Plasminogen Activator Inhibitor-1 (PAI-1) - Full Analysis Set | 0.465 ± 8.5233 | 1.177 ± 8.9405 | -1.792 ± 7.9231 |
Baseline was defined as value obtained on Day 1 (first day of treatment). Adiponectin was measured in milligrams/liter (mg/L) and values obtained through a central laboratory; normal range was 1.20 to 20.00 mg/L.
| mg/L | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set | 1.742 ± 8.6503 | 1.102 ± 2.2116 | 0.050 ± 3.5516 |
Day 1 was first day of treatment. Lactic acidosis defined as elevated blood lactate levels (\>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and increased lactate/pyruvate ratio. Hypoglycemia (low levels of blood glucose) was reported as an adverse event. Safety population included participants who had enrolled in the study and took at least 1 dose of glucophage extended release (glucophage XR). If a subject experienced more than one adverse event, the subject was counted once at the highest severity.
| participants | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Lactic Acidosis | 0 | 0 | 0 |
| Hypoglycemia | 1 | 0 | 0 |
Hematology profile = hematocrit, hemoglobin, red blood cell count (RBC), white blood cell count(WBC), lymphocytes, monocytes, basophils, eosinophils, neutrophils, platelet count. Baseline: value obtained at screening or last value obtained before treatment. LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): \>3 g/dL decrease from preRX; hematocrit (%): \<0.75\*preRX; RBC (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/uL): \<0.67\*LLN or \>1.5\*ULN, of if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; WBC (\*10\^3 c/uL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN, or if preRX\>ULN, use \>1.2\*preRX or \<LLN; neutrophils+bands (\*10\^3 c/uL): if value \<1.0\*10\^3 c/uL; eosinophils (\*10\^3 c/uL): if value \>0.750\*10\^3 c/uL; basophils (\*10\^3 c/uL): if value \>400/mm\^3; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL.
| participants | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline at Week 16 in the Hematology Laboratory Test Profile - Safety Population | 0 | 0 | 0 |
Baseline defined as value obtained either in screening visit or last value obtained before glucophage XR treatment given on Day 1. Serum chemistries evaluating kidney or liver function: blood urea nitrogen(BUN), serum creatinine (SCr), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total bilirubin (BR), uric acid (UA). Abnormal increase in kidney and liver function tests defined as 1.25 - less than, equal to (\<=)2.6 times (x) upper limit of normal (ULN)in ALT, AST, total BR, UA; abnormal increase defined as 1.25 to \<= 5.1 x ULN in BUN. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
| participants | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Number with Week 16 ALT 1.25 to <= 2.6xULN | 2 | 11 | 9 |
| Number with Week 16 ALT > 2.6 x ULN | 0 | 0 | 0 |
| Number with Week 16 AST 1.25 to <= 2.6xULN | 0 | 5 | 4 |
| Number with Week 16 AST > 2.6 x ULN | 0 | 0 | 0 |
| Number with Week 16 Total BR 1.25 to <=2.6xULN | 3 | 2 | 1 |
| Number with Week 16 Total BR > 2.6 x ULN | 0 | 0 | 0 |
| Number with Week 16 BUN1.25 to <=5.1xULN | 0 | 1 | 0 |
| Number with Week 16 BUN > 5.1 x ULN | 0 | 0 | 0 |
| Number with Week 16 UA 1.25 to <=2.6xULN | 3 | 5 | 7 |
| Number with Week 16 UA > 2.6 x ULN | 0 | 0 | 0 |
| Number with Week 16 SCr 1.25 to <=2.6xULN | 0 | 0 | 0 |
| Number with Week 16 SCr > 1.25 x ULN | 0 | 0 | 0 |
Urinalysis included pH and specific gravity. Baseline defined as values obtained at screening visit. Clinically significant: outside the reference range (low/high)and judged to be significant by the investigator: Specific gravity 1.003 - 1.035; ph 5 - 8. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
| participants | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline at Week 16 in Urinalysis - Safety Population | 0 | 0 | 0 |
Baseline was defined as ECG obtained at the screening visit. ECG was 12-lead. Heart rate (HR) was measured in beats per minute (beats/min). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
| beats/min | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Mean Change From Baseline at Week at Week 16 in ECG Parameter Heart Rate (HR) - Safety Population | 0.4 ± 8.91 | 1.2 ± 9.56 | 1.1 ± 12.36 |
Baseline was defined as the value obtained at screening or value obtained on Day 1 before treatment. Diastolic and systolic blood pressure was measured in millimeters of mercury (mm Hg). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
| mm Hg | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Week 16 change in diastolic blood pressure | -2.2 ± 8.63 | -4.1 ± 9.31 | -1.4 ± 9.37 |
| Week 16 change in systolic blood pressure | -4.6 ± 14.21 | -5.5 ± 12.14 | -1.7 ± 14.55 |
Baseline was defined as ECG obtained at the screening visit. A judgment of clinical significance was at the discretion of the investigator. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.
| participants | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population | 0 | 1 | 3 |
Collected over 16 Weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glucophage XR in Normal Weight Participants | — | 1/125 (0.8%) | 43/125 (34.4%) |
| Glucophage XR in Overweight Participants | — | 0/122 (0%) | 47/122 (38.5%) |
| Glucophage XR in Obese Participants | — | 1/124 (0.8%) | 46/124 (37.1%) |
| Event | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| HypertensionBlood and lymphatic system disorders | 0/125 | 0/122 | 1/124 |
| Right upper lung cancerRespiratory, thoracic and mediastinal disorders | 1/125 | 0/122 | 0/124 |
| Event | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 18/125 | 12/122 | 4/124 |
| Abdominal discomfortGastrointestinal disorders | 2/125 | 13/122 | 2/124 |
| Abdominal distensionGastrointestinal disorders | 6/125 | 9/122 | 2/124 |
| HyperuricemiaMetabolism and nutrition disorders | 0/125 | 2/122 | 6/124 |
| DizzinessNervous system disorders | 6/125 | 4/122 | 4/124 |
| palpitationsCardiac disorders | 6/125 | 4/122 | 1/124 |
| NauseaGastrointestinal disorders | 2/125 | 5/122 | 4/124 |
| ConstipationGastrointestinal disorders | 4/125 | 1/122 | 2/124 |
| Abdominal pain upperGastrointestinal disorders | 3/125 | 3/122 | 2/124 |
| FatigueGeneral disorders | 0/125 | 3/122 | 1/124 |
Baseline population consisted of: all participants enrolled into one of three body weight arms, normal, overweight or obese, based on body mass index at screening; and who were assigned to treatment with Glucophage XR. This population was used for analysis of demographics.
| Age Continuous(years) | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants | Total |
|---|---|---|---|---|
| Median | 53.0 ± 10.32 | 51.0 ± 9.21 | 52.5 ± 10.97 | 52.0 ± 10.17 |
| Sex: Female, Male(Participants) | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants | Total |
|---|---|---|---|---|
| Female | 64 | 45 | 52 | 161 |
| Male | 61 | 77 | 72 | 210 |
| Region of Enrollment(participants) | Glucophage XR in Normal Weight Participants | Glucophage XR in Overweight Participants | Glucophage XR in Obese Participants | Total |
|---|---|---|---|---|
| China | 125 | 122 | 124 | 371 |
The record gives a start of Nov 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin